Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibuprofen + acetaminophen
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ibuprofen + acetaminophen is a combination analgesic regimen consisting of 400 mg of ibuprofen and 1000 mg of acetaminophen. This specific combination was the subject of a randomized, double-blind clinical trial conducted at Montefiore Medical Center to evaluate its efficacy in treating acute musculoskeletal extremity pain in the emergency department. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that acts by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the production of pro-inflammatory prostaglandins. Acetaminophen is a non-opioid analgesic and antipyretic that primarily acts within the central nervous system, though its exact mechanism is complex and may involve inhibition of COX-3 and modulation of the endocannabinoid system. The Montefiore study demonstrated that this combination provides pain relief comparable to opioid-acetaminophen combinations (such as oxycodone/acetaminophen), supporting its use as an effective non-opioid alternative for acute pain management.
- Brand names
- TylenolAdvilMotrin
- Other names
- ibuprofen/acetaminophenacetaminophen/ibuprofen
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on ibuprofen + acetaminophen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibuprofen + acetaminophen.